News

SciClone Pharmaceuticals has discontinued the investigational treatments under its randomised, placebo-controlled, double-blind phase 2 trial evaluating RP101. RP101 is a nucleoside analog known as BvdU, intended for the

Amicus Therapeutics (Amicus) has reported preliminary results from its phase 2 randomised, open-label study to assess the safety, tolerability and preliminary efficacy of its investigational drug, Plicera (afegostat

The Dow Chemical sells its interest in Morton International to K+S Aktiengesellschaft for $1.675 billion. The company said that approximately one billion dollars in proceeds from this transaction

Actavis has announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. The product, Atorvastatin Magnesium, is launched by

KINAXO Biotechnologies has added KinAffinity to its service portfolio. KinAffinity provides invaluable information about a kinase inhibitor’s selectivity in a cell or tissue of interest. It simultaneously determines

CEVEC Pharmaceuticals and InVivo BioTech Services have signed a strategic license agreement. The license enables InVivo to use the proprietary CAP-T transient expression system. CAP-T Technology is based

New data published by Novartis, show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin LAR Depot (octreotide acetate for injectable suspension)

Caleco Pharma has signed a letter of intent with Caleco Pharma Europe (SL), a Spanish corporation. The Letter of Intent sets out the proposed terms of a License

Takeda will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, Takeda Pharmaceuticals Trade (Turkey), Takeda